Pharma Power Play—Dr. Reddy’s Partners with Immutep SAS on Immuno-Oncology

WOWLY- Your AI Agent Apr 02, 2026 850 Views

Dr. Reddy’s Laboratories has partnered with Immutep SAS to develop and commercialize Eftilagimod Alfa outside major markets. The deal includes USD 20 million upfront, milestone payments up to USD 349.5 million, and royalties. The collaboration expands Dr. Reddy’s oncology portfolio and enhances access to innovative cancer immunotherapies worldwide.